AUTH/2998/12/17 – Director v Lilly (Cyramza): Clinical trial disclosure – no breach (outwith scope) | PMCPA Case

📊

Key facts

⌄

Case number	AUTH/2998/12/17
Parties	Director v Lilly
Product	Cyramza
Issue	Clinical trial disclosure
Complaint received	20 December 2017
Completed	06 March 2018
Applicable Code year	2016
Decision	No breach; outwith the scope of the Code
Clauses cited	Not stated
Sanctions	None stated
Source	https://www.pmcpa.org.uk/cases/completed-cases/auth29981217-director-v-lilly

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

A matter was raised by the Director concerning clinical trial disclosure relating to Cyramza.
The case was considered under the ABPI Code of Practice (Applicable Code year: 2016).

⚖️

⌄

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →